Skip to main content
Top
Published in: Advances in Therapy 2/2020

Open Access 01-02-2020 | Review

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review

Authors: Daniel E. Hilleman, Barbara S. Wiggins, Michael B. Bottorff

Published in: Advances in Therapy | Issue 2/2020

Login to get access

Abstract

Introduction

Currently available omega-3 (OM-3) fatty acid products in the US are either nonprescription dietary supplements (e.g., fish oils) or prescription (Rx) medications. As such, we aimed to describe critical therapeutic differences among the OM-3 fatty acids, focusing on differences between fish oil supplements and Rx OM-3s.

Methods

A narrative review of known papers salient to this topic was conducted.

Results

Despite the multiple purported clinical benefits, the published evidence for OM-3 dietary supplements is generally insufficient, inconsistent, or negative. Rx OM-3 products are indicated as an adjunct to diet to reduce triglycerides (TG) in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dl). Recently, the Rx eicosapentaenoic acid (EPA)-only OM-3, icosapent ethyl, demonstrated cardiovascular (CV) risk reduction among statin-treated patients at high risk of CV disease in a large CV outcomes trial (CVOT), and is now also indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥ 150 mg/dL) and established CVD or diabetes mellitus and ≥ 2 additional risk factors for CVD. In contrast to the rigorous regulatory standards for safety, efficacy, and manufacturing of medications (whether Rx or over the counter), the Food and Drug Administration manages dietary supplements as food. Issues specific to OM-3 dietary supplements include variable content, labeling inconsistencies, and poor product quality/impurity. Given these issues, OM-3 dietary supplements should not be substituted for Rx OM-3 products. The efficacy of the EPA-only Rx OM-3 product in a large CVOT cannot be extrapolated to other OM-3 products.

Conclusion

Consumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
Literature
1.
go back to reference Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–66.PubMedCrossRef Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–66.PubMedCrossRef
2.
go back to reference Nelson JR, True WS, Le V, Mason RP. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med. 2017;129:822–7.PubMedCrossRef Nelson JR, True WS, Le V, Mason RP. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med. 2017;129:822–7.PubMedCrossRef
3.
go back to reference Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol. 2016;67:22–7.PubMedCrossRef Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol. 2016;67:22–7.PubMedCrossRef
4.
go back to reference Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.PubMedCrossRef Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.PubMedCrossRef
5.
go back to reference Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.PubMedCrossRef Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.PubMedCrossRef
6.
go back to reference Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5–18.PubMedCrossRef Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5–18.PubMedCrossRef
7.
go back to reference Fialkow J. Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products. Am J Cardiovasc Drugs. 2016;16:229–39.PubMedPubMedCentralCrossRef Fialkow J. Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products. Am J Cardiovasc Drugs. 2016;16:229–39.PubMedPubMedCentralCrossRef
8.
go back to reference Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2019. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2019.
9.
go back to reference Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.PubMedCrossRef Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.PubMedCrossRef
10.
go back to reference ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540–50.CrossRef ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540–50.CrossRef
11.
go back to reference Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23–32.PubMedCrossRef Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23–32.PubMedCrossRef
12.
go back to reference Hilleman DE, Teply R, Packard KA. Knowledge, perceptions, and patterns of fish oil use in cardiac patients. J Pharm Pract. 2019;1:0897190018824485. Hilleman DE, Teply R, Packard KA. Knowledge, perceptions, and patterns of fish oil use in cardiac patients. J Pharm Pract. 2019;1:0897190018824485.
13.
go back to reference Backes JM, Melton BL, Ruisinger JF, Burkhardt CD, Moriarty PM. A comparison of patients’ prescribed, self-reported, and actual-intake of supplemental EPA/DHA [poster 161]. National Lipid Association Scientific Sessions, 2016 May 19–20, New Orleans LA; 2016. Backes JM, Melton BL, Ruisinger JF, Burkhardt CD, Moriarty PM. A comparison of patients’ prescribed, self-reported, and actual-intake of supplemental EPA/DHA [poster 161]. National Lipid Association Scientific Sessions, 2016 May 19–20, New Orleans LA; 2016.
15.
go back to reference Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;1:46B–52B. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;1:46B–52B.
16.
go back to reference Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. Pharm Ther. 2013;38:681–91. Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. Pharm Ther. 2013;38:681–91.
17.
go back to reference Ito MK. A comparative overview of prescription omega-3 fatty acid products. Pharm Ther. 2015;40:826–57. Ito MK. A comparative overview of prescription omega-3 fatty acid products. Pharm Ther. 2015;40:826–57.
18.
go back to reference Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017. Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
19.
go back to reference Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
20.
go back to reference Omtryg [package insert]. Arlington, VA: Trygg Pharma, Inc.; 2014. Omtryg [package insert]. Arlington, VA: Trygg Pharma, Inc.; 2014.
21.
go back to reference Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–e691PubMedCrossRef Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–e691PubMedCrossRef
22.
go back to reference Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:Cd003177.PubMed Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:Cd003177.PubMed
23.
go back to reference Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e867–84.PubMedPubMedCentralCrossRef Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e867–84.PubMedPubMedCentralCrossRef
24.
go back to reference Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20:107–20.PubMedCrossRef Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20:107–20.PubMedCrossRef
25.
go back to reference Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018;3:225–34.PubMedCrossRef Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018;3:225–34.PubMedCrossRef
26.
go back to reference GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.CrossRef GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.CrossRef
27.
go back to reference Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.PubMedCrossRef Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.PubMedCrossRef
28.
go back to reference Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.PubMedCrossRef Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.PubMedCrossRef
29.
go back to reference Nosaka K, Miyoshi T, Iwamoto M, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2017;228:173–9.PubMedCrossRef Nosaka K, Miyoshi T, Iwamoto M, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2017;228:173–9.PubMedCrossRef
31.
go back to reference Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;2019:1–78. Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;2019:1–78.
33.
go back to reference Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin treated patients with high levels of triglycerides and low levels of high density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281–8.PubMedPubMedCentralCrossRef Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin treated patients with high levels of triglycerides and low levels of high density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281–8.PubMedPubMedCentralCrossRef
34.
go back to reference Senftleber NK, Nielsen SM, Andersen JR, et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients. 2017;9:1.CrossRef Senftleber NK, Nielsen SM, Andersen JR, et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients. 2017;9:1.CrossRef
35.
go back to reference Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: a systematic review. Nutr Neurosci. 2018;21:529–38.PubMedCrossRef Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: a systematic review. Nutr Neurosci. 2018;21:529–38.PubMedCrossRef
36.
go back to reference Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012;20:Cd005379. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012;20:Cd005379.
37.
go back to reference Evans JR, Lawrenson JG. A review of the evidence for dietary interventions in preventing or slowing the progression of age-related macular degeneration. Ophthalm Physiol Opt. 2014;34:390–6.CrossRef Evans JR, Lawrenson JG. A review of the evidence for dietary interventions in preventing or slowing the progression of age-related macular degeneration. Ophthalm Physiol Opt. 2014;34:390–6.CrossRef
38.
go back to reference Newberry SJ, Chung M, Booth M, et al. Omega-3 fatty acids and maternal and child health: an updated systematic review. Evid Rep Technol Assess. 2016;20:1–826. Newberry SJ, Chung M, Booth M, et al. Omega-3 fatty acids and maternal and child health: an updated systematic review. Evid Rep Technol Assess. 2016;20:1–826.
39.
go back to reference Sunderic M, Robajac D, Gligorijevic N, et al. Is there something fishy about fish oil? Curr Pharm Des. 2019;25:1747–59.PubMedCrossRef Sunderic M, Robajac D, Gligorijevic N, et al. Is there something fishy about fish oil? Curr Pharm Des. 2019;25:1747–59.PubMedCrossRef
40.
go back to reference Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176:473–82.PubMedPubMedCentralCrossRef Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176:473–82.PubMedPubMedCentralCrossRef
41.
go back to reference Cohen PA. The supplement paradox: negligible benefits, robust consumption. JAMA. 2016;316:1453–4.PubMedCrossRef Cohen PA. The supplement paradox: negligible benefits, robust consumption. JAMA. 2016;316:1453–4.PubMedCrossRef
42.
44.
go back to reference Cohen PA. Hazards of hindsight–monitoring the safety of nutritional supplements. N Engl J Med. 2014;370:1277–80.PubMedCrossRef Cohen PA. Hazards of hindsight–monitoring the safety of nutritional supplements. N Engl J Med. 2014;370:1277–80.PubMedCrossRef
45.
go back to reference Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and Blue Cross of Idaho. LipidSpin. 2010;8:32–4. Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and Blue Cross of Idaho. LipidSpin. 2010;8:32–4.
47.
go back to reference Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr. 2008;27:659–66.PubMedCrossRef Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr. 2008;27:659–66.PubMedCrossRef
50.
go back to reference Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018;1:e183337.PubMedPubMedCentralCrossRef Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018;1:e183337.PubMedPubMedCentralCrossRef
51.
go back to reference Harel Z, Harel S, Wald R, Mamdani M, Bell CM. The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med. 2013;173:926–8.PubMedCrossRef Harel Z, Harel S, Wald R, Mamdani M, Bell CM. The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med. 2013;173:926–8.PubMedCrossRef
52.
go back to reference Funk RS, Singh RK, Winefield RD, et al. Variability in potency among commercial preparations of berberine. J Diet Suppl. 2018;15:343–51.PubMedCrossRef Funk RS, Singh RK, Winefield RD, et al. Variability in potency among commercial preparations of berberine. J Diet Suppl. 2018;15:343–51.PubMedCrossRef
55.
go back to reference Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40.PubMedPubMedCentralCrossRef Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40.PubMedPubMedCentralCrossRef
56.
go back to reference Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Rep. 2015;20:1–16. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Rep. 2015;20:1–16.
57.
go back to reference Shim SM, Santerre CR, Burgess JR, Deardorff DC. Omega-3 fatty acids and total polychlorinated biphenyls in 26 dietary supplements. J Food Sci. 2003;68:2436–40.CrossRef Shim SM, Santerre CR, Burgess JR, Deardorff DC. Omega-3 fatty acids and total polychlorinated biphenyls in 26 dietary supplements. J Food Sci. 2003;68:2436–40.CrossRef
58.
go back to reference Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015;95:1260–7.PubMedCrossRef Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015;95:1260–7.PubMedCrossRef
59.
go back to reference Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013;93:1935–9.PubMedCrossRef Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013;93:1935–9.PubMedCrossRef
60.
go back to reference Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun. 2017;483:425–9.PubMedCrossRef Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun. 2017;483:425–9.PubMedCrossRef
61.
go back to reference Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.PubMedPubMedCentralCrossRef Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.PubMedPubMedCentralCrossRef
62.
go back to reference Tur JA, Bibiloni MM, Sureda A, Pons A. Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr. 2012;107(Suppl 2):S23–52.PubMedCrossRef Tur JA, Bibiloni MM, Sureda A, Pons A. Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr. 2012;107(Suppl 2):S23–52.PubMedCrossRef
64.
go back to reference Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract P72]. Circulation. 2007;115:e238. Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract P72]. Circulation. 2007;115:e238.
65.
go back to reference Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord. 2011;9:255–71.PubMedCrossRef Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord. 2011;9:255–71.PubMedCrossRef
66.
go back to reference Jackowski SA, Alvi AZ, Mirajkar A, et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci. 2015;4:e30.PubMedPubMedCentralCrossRef Jackowski SA, Alvi AZ, Mirajkar A, et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci. 2015;4:e30.PubMedPubMedCentralCrossRef
67.
go back to reference Nogueira MS, Kessuane MC, Lobo Ladd AA, Lobo Ladd FV, Cogliati B, Castro IA. Effect of long-term ingestion of weakly oxidised flaxseed oil on biomarkers of oxidative stress in LDL-receptor knockout mice. Br J Nutr. 2016;20:1–12. Nogueira MS, Kessuane MC, Lobo Ladd AA, Lobo Ladd FV, Cogliati B, Castro IA. Effect of long-term ingestion of weakly oxidised flaxseed oil on biomarkers of oxidative stress in LDL-receptor knockout mice. Br J Nutr. 2016;20:1–12.
68.
go back to reference Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, Micol V, Roche E, Garcia-Garcia E. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int J Food Sci Nutr. 2013;64:993–1000.PubMedCrossRef Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, Micol V, Roche E, Garcia-Garcia E. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int J Food Sci Nutr. 2013;64:993–1000.PubMedCrossRef
69.
go back to reference Akesson A, Donat-Vargas C, Berglund M, Glynn A, Wolk A, Kippler M. Dietary exposure to polychlorinated biphenyls and risk of heart failure—a population-based prospective cohort study. Environ Int. 2019;126:1–6.PubMedCrossRef Akesson A, Donat-Vargas C, Berglund M, Glynn A, Wolk A, Kippler M. Dietary exposure to polychlorinated biphenyls and risk of heart failure—a population-based prospective cohort study. Environ Int. 2019;126:1–6.PubMedCrossRef
71.
go back to reference Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.PubMedCrossRef Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.PubMedCrossRef
72.
go back to reference Grey A, Bolland M. Clinical trial evidence and use of fish oil supplements. JAMA Intern Med. 2014;174:460–2.PubMedCrossRef Grey A, Bolland M. Clinical trial evidence and use of fish oil supplements. JAMA Intern Med. 2014;174:460–2.PubMedCrossRef
74.
go back to reference American Diabetes Association. Standards of medical care in diabetes—2019. Diabetes Care. 2019;41(suppl 1):S1–193. American Diabetes Association. Standards of medical care in diabetes—2019. Diabetes Care. 2019;41(suppl 1):S1–193.
Metadata
Title
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review
Authors
Daniel E. Hilleman
Barbara S. Wiggins
Michael B. Bottorff
Publication date
01-02-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 2/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01211-1

Other articles of this Issue 2/2020

Advances in Therapy 2/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.